Teplizumab shows expanded FDA approval for delaying stage 3 type 1 diabetes in younger children, suggesting broader treatment options.
The CD3-directed monoclonal antibody teplizumab (Tzield – Provention Bio), which was previously approved by the FDA to delay the onset of stage 3 type 1 diabetes in patients ≥8 years old with stage 2 type 1 diabetes, has now been approved for such use in children 1-7 years old.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: